Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cencora ( (COR) ) has shared an update.
On September 3, 2025, Cencora announced a court-approved agreement to resolve a stockholder derivative action filed by the Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan. The complaint, initiated on December 30, 2021, alleged breaches of fiduciary duty related to the oversight of Cencora’s controlled substance diversion control programs. The settlement, reached after a successful mediation, involves insurance carriers paying Cencora $111.3 million, excluding legal fees, without any admission of liability from the defendants. This resolution marks a significant step in addressing claims against the company’s management and could impact its financial standing and stakeholder relations.
The most recent analyst rating on (COR) stock is a Hold with a $306.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
Cencora’s overall stock score reflects strong earnings performance and raised guidance, which are offset by high leverage and valuation concerns. The technical indicators suggest a neutral market sentiment, while the company’s strategic initiatives provide a positive outlook.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc., formerly known as AmerisourceBergen Corporation, operates in the pharmaceutical distribution industry, focusing on the distribution of controlled substances, including opioids.
Average Trading Volume: 1,261,592
Technical Sentiment Signal: Buy
Current Market Cap: $56.54B
For detailed information about COR stock, go to TipRanks’ Stock Analysis page.